Nancy Rahnma, M.D., a board-certified internist and obesity medicine specialist with a private practice in Beverly Hills. Agreed: celebrity use, or abuse, of these weight loss drugs (not for health reasons, but simply to achieve their ideal figure) is very problematic due to the pervasiveness of weight loss culture, Dr. Rahnma it is said.
Since a thin waist is considered health,what exactly is this drugWhich are now constantly being named, and who should (and, more importantly, who shouldn’t) take them?
What is Ozempic?
semaglutideWhich one is that Ozempic Active Ingredient, belongs to a class of drugs called GLP-1 agonists. these compounds reproduce a hormone Which we all make in our intestines and which comes out after we start eating.
,Semaglutide enhances insulin release in response to glucose intake and causes a slight delay in gastric emptying,’ explains Dr. Arianna Chao, MD, an associate professor at the University of Pennsylvania School of Nursing and medical director of the school’s Center for Weight and Eating Disorders, ‘and also works in areas related to appetite. and regulation of food intake’.
The drug also makes the body more sensitive to insulin, says Dr. Holly Lofton says “Doing this helps your body’s fat cells shrink over time,” Dr. Lofton explains.
Novo Nordisk produces both Ozempic and Vegovy semaglutide., which, although approved for two different purposes, are in fact identical. semaglutide 1 mg (Ozempic) is approved by injection once a week Food and Drug Association of the United States (FDA) To treat diabetes since 2017. A higher dose of 2 mg was approved in early 2022,’ says W. Scott Busch, MD, MSc, director of obesity medicine at the Cleveland Clinic’s Bariatric and Metabolic Institute. “Vegovy is a higher dose of weekly semaglutide (2.4 mg) that was approved in July 2021 for the treatment of obesity.”
Is Ozempic FDA Approved For Weight Loss?
Not necessary. Wegovy is approved for weight loss in adults 18 years of age and older who have a body mass index (BMI) of 30 or higher, or a BMI of 27 plus a comorbidity, such as high cholesterol or high blood pressure. Doctor. ‘Vegov ushers in a new generation of highly effective anti-obesity drugs,’ Busch says, ‘reducing 12.4% body weight in a 68-week randomized controlled trial of more than 1,900 people with an average BMI of 37. was better than Antiobesity drugs. In addition, more than half of the study group (55%) lost more than 15% and 20% to 35% of body weight.